934536-10-4

Upstream product

• 211108-48-4 tert-butyl 4-[(trimethylsilyl)oxy]-3,6-dihydropyridine-1(2H)-carboxylate 
• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 373604-28-5 3-fluoro-4-hydroxypiperidine-1-carboxylic acid tert-butyl ester 
• 1070896-84-2 tert-butyl 3-fluoro-4-((methylsulfonyl)oxy)piperidine-1-carboxylate 
• 110-86-1 pyridine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 211108-50-8 tert-butyl-3-fluoro-4-oxopiperidine-1-carboxylate 

Downstream Products

• 934536-11-5 4-Benzyloxycarbonylamino-3-fluoro-piperidine-1-carboxylic acid tert-butyl ester 
• 934536-09-1 tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3R,4R)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 211108-52-0 (3S,4S)-tert-butyl 4-(benzylamino)-3-fluoropiperidine-1-carboxylate 
• 1260612-08-5 (3R,4R)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 577691-56-6 (3S,4S)-tert-butyl 4-amino-3-fluoropiperidine-1-carboxylate 
• 1033748-75-2 (3S,4R)-tert-butyl 4-(((benzyloxy)carbonyl)amino)-3-fluoropiperidine-1-carboxylate 
• 1351866-21-1 (3R,4S)-tert-butyl 4-(((benzyloxy)carbonyl)amino)-3-fluoropiperidine-1-carboxylate 

Relevant academic research and scientific papers

PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES

Disclosed are compounds of Formula (1), stereoisomers thereof, and pharmaceutically acceptable salts thereof, wherein L, r, s, R5, R6,R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with SSTR4.

CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme ceramide galactosyltransferase (CGT), such as, for example, lysosomal storage diseases. Examples of lysosomal storage diseases include, for example, Krabbe disease and Metachromatic Leukodystrophy.

5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them

The disclosure relates particularly to certain carboxamide, sulfonamide and amine compounds and pharmaceutical compositions thereof, and to methods of treating and ameliorating disorders and conditions related to the adiponectin pathway, sphingolipid metabolism, oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. In certain embodiments, the compounds have the structures (I-1), (2-I) and (3-I) in which the variables are as described herein.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF MEK

The present invention relates to compounds of formula I in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.

Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy

The pyrrolamides are a new class of antibacterial agents targeting DNA gyrase, an essential enzyme across bacterial species and inhibition results in the disruption of DNA synthesis and subsequently, cell death. The optimization of biochemical activity an

5-Quinoline derivatives having an anti-bacterial activity

The present invention describes novel anti-bacterial compounds of the formula (I). These compounds are, amongst others, of interest as inhibitors of DNA gyrase and topoisomerases, for example of topoisomerase II and IV.

N-PIPERIDINE DERIVATES AS CCR3 MODULATORS

Compounds of formula I, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dement